Valproic acid alters mitochondrial cholesterol transport in Y1 adrenocortical cells

Toxicology in Vitro

Volumn 25, Issue 1, 2011, Pages 7-12

  Brion, L ^a   Gorostizaga, A ^a   Gomez N V ^a   Podesta E J ^a   Cornejo Maciel, F ^a   Paz, C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Adrenocorticotropin; Cholesterol; StAR protein; Steroidogenesis; Valproic acid

Indexed keywords

CYCLIC AMP; MESSENGER RNA; PROGESTERONE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; VALPROIC ACID;

ADRENAL CORTEX CELL; ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL LEVEL; CELL STIMULATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; HORMONE ACTION; INTRACELLULAR TRANSPORT; MITOCHONDRION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROGESTERONE RELEASE; PROTEIN FUNCTION; PROTEIN TRANSPORT;

3-HYDROXYSTEROID DEHYDROGENASES; ADRENAL CORTEX; ANIMALS; ANTICONVULSANTS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CYCLIC AMP; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENES, REPORTER; MICE; MITOCHONDRIA; PHOSPHOPROTEINS; PROGESTERONE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; VALPROIC ACID;

EID: 78650524127     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.08.006     Document Type: Article

References (47)

1. Artemenko I.P., Jefcoate C.R. Multiple contributions from long-chain fatty acid metabolism in Y-1 and MA-10 cells. Endocr. Res. 2004, 30:637.
2. Aydin K., Serdaroglu A., Okuyaz C., Bideci A., Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 2005, 20:848-851.
3. Bey P., Gorostizaga A.B., Maloberti P.M., Lozano R.C., Poderoso C., Maciel F.C., Podesta E.J., Paz C. Adrenocorticotropin induces mitogen-activated protein kinase phosphatase 1 in Y1 mouse adrenocortical tumor cells. Endocrinology 2003, 144:1399-1406.
4. Bilo L., Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol. Endocrinol. 2008, 24:562-570.
5. Bose M., Whittal R.M., Miller W.L., Bose H.S. Steroidogenic activity of StAR requires contact with mitochondrial VDAC1 and phosphate carrier protein. J. Biol. Chem. 2008, 283:8837-8845.
6. Byrne G.C., Perry Y.S., Winter J.S. Steroid inhibitory effects upon human adrenal 3 beta-hydroxysteroid dehydrogenase activity. J. Clin. Endocrinol. Metab. 1986, 62:413-418.
7. Castillo A.F., Maciel F.C., Castilla R., Duarte A., Maloberti P., Paz C., Podesta E.J. CAMP increases mitochondrial cholesterol transport through the induction of arachidonic acid release inside this organelle in Leydig cells. FEBS J. 2006, 273:5011-5021.
8. Clark B.J., Wells J., King S.R., Stocco D.M. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J. Biol. Chem. 1994, 269:28314-28322.
9. Cornejo Maciel F., Maloberti P., Neuman I., Cano F., Castilla R., Castillo F., Paz C., Podesta E.J. An arachidonic acid-preferring acyl-CoA synthetase is a hormone-dependent and obligatory protein in the signal transduction pathway of steroidogenic hormones. J. Mol. Endocrinol. 2005, 34:655-666.
10. Crivello J.F., Jefcoate C.R. Intracellular movement of cholesterol in rat adrenal cells. Kinetics and effects of inhibitors. J. Biol. Chem. 1980, 255:8144-8151.
11. Chen W.Y., Weng J.H., Huang C.C., Chung B.C. Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol. Cell. Biol. 2007, 27:7284-7290.
12. Duarte A., Castillo A.F., Castilla R., Maloberti P., Paz C., Podesta E.J., Cornejo Maciel F. An arachidonic acid generation/export system involved in the regulation of cholesterol transport in mitochondria of steroidogenic cells. FEBS Lett. 2007, 581:4023-4028.
13. Ellis D.J., Lawman Z.K., Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 2008, 367:656-662.
14. Gazdar A.F., Oie H.K., Shackleton C.H., Chen T.R., Triche T.J., Myers C.E., Chrousos G.P., Brennan M.F., Stein C.A., La Rocca R.V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 1990, 50:5488-5496.
15. Genton P., Bauer J., Duncan S., Taylor A.E., Balen A.H., Eberle A., Pedersen B., Salas-Puig X., Sauer M.V. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001, 42:295-304.
16. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 2004, 83(Suppl. 1). S91-92.
17. Gurvich N., Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 2002, 96:45-66.
18. Gustavsen M.W., von Krogh K., Tauboll E., Zimmer K.E., Dahl E., Olsaker I., Ropstad E., Verhaegen S. Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol. Scand. 2009, (Suppl.):14-21.
19. Invitti C., Danesi L., Dubini A., Cavagnini F. Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol. (Copenh) 1988, 118:381-388.
20. Kessel A., Musafia B., Ben-Tal N. Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer. Biophys. J. 2001, 80:2536-2545.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Luís P.B.M., Ruiter J.P.N., Aires C.C.P., Soveral G., Tavares de Almeida I., Duran M., Wanders R.J.A., Silva M.F.B. Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation. Biochim. Biophys. Acta (BBA) - Bioenerg. 2007, 1767:1126-1133.
23. Martin L.J., Tremblay J.J. The nuclear receptors NUR77 and SF1 play additive roles with c-JUN through distinct elements on the mouse star promoter. J. Mol. Endocrinol. 2009, 42:119-129.
24. Miller W.L. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids 2007, 1771:663-676.
25. Neher R., Milani A., Solano A.R., Podesta E.J. Compartmentalization of corticotropin-dependent steroidogenic factors in adrenal cortex: evidence for a post-translational cascade in stimulation of the cholesterol side-chain split. Proc. Natl. Acad. Sci. USA 1982, 79:1727-1731.
26. Nelson-DeGrave V.L., Wickenheisser J.K., Cockrell J.E., Wood J.R., Legro R.S., Strauss J.F., McAllister J.M. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004, 145:799-808.
27. Parker K.L., Schimmer B.P. Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr. Rev. 1997, 18:361-377.
28. Paz C., Cornejo Maciel F., Maloberti P., Walsh L.P., Stocco D.M., Podesta E.J. Protein tyrosine phosphatases are involved in LH/chorionic gonadotropin and 8Br-cAMP regulation of steroidogenesis and StAR protein levels in MA-10 Leydig cells. J. Endocrinol. 2002, 175:793-801.
29. Perlman B.J., Goldstein D.B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol. Pharmacol. 1984, 26:83-89.
30. Poderoso C., Converso D.P., Maloberti P., Duarte A., Neuman I., Galli S., Maciel F.C., Paz C., Carreras M.C., Poderoso J.J., Podesta E.J. A mitochondrial kinase complex is essential to mediate an ERK1/2-dependent phosphorylation of a key regulatory protein in steroid biosynthesis. PLoS ONE 2008, 3:e1443.
31. Pylvanen V., Pakarinen A., Knip M., Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006, 8:643-648.
32. Rasgon N.L., Altshuler L.L., Fairbanks L., Elman S., Bitran J., Labarca R., Saad M., Kupka R., Nolen W.A., Frye M.A., Suppes T., McElroy S.L., Keck P.E., Leverich G., Grunze H., Walden J., Post R., Mintz J. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord. 2005, 7:246-259.
33. Rattya J., Pakarinen A.J., Knip M., Repo-Outakoski M., Myllyla V.V., Isojarvi J.I. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001, 57:440-444.
34. Roste L.S., Tauboll E., Berner A., Isojarvi J.I., Gjerstad L. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp. Toxicol. Pathol. 2001, 52:545-552.
35. Schimmer B.P. Adrenocortical Y1 cells. Methods Enzymol. 1979, 58:570-574.
36. Stocco D.M., Clark B.J. Regulation of the acute production of steroids in steroidogenic cells. Endocr. Rev. 1996, 17:221-244.
37. Stout S.C., Owens M.J., Lindsey K.P., Knight D.L., Nemeroff C.B. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology 2001, 24:624-631.
38. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998, 12:599-606.
39. Sugawara T., Kiriakidou M., McAllister J.M., Kallen C.B., Strauss J.F. Multiple steroidogenic factor 1 binding elements in the human steroidogenic acute regulatory protein gene 5'-flanking region are required for maximal promoter activity and cyclic AMP responsiveness. Biochemistry 1997, 36:7249-7255.
40. Sveberg Roste L., Tauboll E., Berner A., Berg K.A., Aleksandersen M., Gjerstad L. Morphological changes in the testis after long-term valproate treatment in male Wistar rats. Seizure 2001, 10:559-565.
41. Tauboll E., Gregoraszczuk E.L., Tworzydo A., Wojtowicz A.K., Ropstad E. Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells. Epilepsia 2006, 47:1580-1583.
42. Tauboll E., Wojtowicz A.K., Ropstad E., Gregoraszczuk E.L. Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro. Reprod. Toxicol. 2002, 16:319-325.
43. Tong V., Teng X.W., Chang T.K.H., Abbott F.S. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005, 86:436-443.
44. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76:4350-4354.
45. Tsai S.C., Lu C.C., Lin C.S., Wang P.S. Antisteroidogenic actions of hydrogen peroxide on rat Leydig cells. J. Cell. Biochem. 2003, 90:1276-1286.
46. Verrotti A., Manco R., Agostinelli S., Coppola G., Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2009, 51:268-273.
47. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 2001, 276:31674-31683.